ZymeTx seeks approval for influenza diagnostics:
This article was originally published in Clinica
Executive Summary
ZymeTx has submitted two 510(k) applications for laboratory tests based on its ViraSTAT technology that can distinguish between the two most common forms of influenza. The ability to differentiate influenza A from B is valuable in tracking the spread of the virus and developing more effective vaccines and treatments, says Peter Livingston, the company's president and CEO. Oklahoma City-based ZymeTx has also agreed a US distribution deal with Fisher Scientific for its FDA-approved ViraSTAT-based diagnostic tests for parainfluenza and influenza A/B.